Beta-lactam antibiotics by intermittent infusion
|
Sample A: mid-way through dosing interval (50% of dosing interval)
|
· 50% f T>MIC
|
(amoxycillin-clavulanate; ampicillin; piperacillin-tazobactam; penicillin-G; flucloxacillin; dicloxacillin; cloxacillin; cephazolin; ceftazidime; ceftriaxone; cefepime; meropenem; imipenem; doripenem; ertapenem)
|
Sample B: within 30 min of next dose (100% of dosing interval)
|
· 50% f T>4xMIC*
|
Glycopeptide antibiotics by intermittent infusion (vancomycin, teicoplanin)
| |
· 100% f T>MIC
|
| |
· 100% f T>4xMIC
|
| |
· 100% f T>4xMIC
|
| |
· Concentration ≥15 mg/L*
|
Triazole antifungals (fluconazole, voriconazole)
|
Sample A: 30 min after completion of intravenous infusion (peak concentration)
|
· AUC0-24/MIC ≥25*
|
Echinocandin antifungals (caspofungin, micafungin, anidulafungin)
|
Sample B: mid-way through dosing interval (50% of dosing interval)
|
· AUC0-24/MIC ≥20*
|
|
Sample C: within 30 min of next dose (100% of dosing interval)
| |
Beta-lactam antibiotics (listed above) by continuous infusion
|
Sample A: at any time
|
· 100% f T>4xMIC*
|
|
Sample B: >6 hours after sample A
| |
Glycopeptide antibiotics (listed above) by continuous infusion
| |
· 100% f T>4xMIC*
|
| |
· AUC0-24/MIC ≥350
|